MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ
2.000
0.000
0.00%
After Hours: 2.050 +0.05 +2.50% 17:29 05/17 EDT
OPEN
2.050
PREV CLOSE
2.000
HIGH
2.100
LOW
1.950
VOLUME
263.46K
TURNOVER
0
52 WEEK HIGH
3.790
52 WEEK LOW
1.080
MARKET CAP
130.93M
P/E (TTM)
-1.3711
1D
5D
1M
3M
1Y
5Y
Regulus Sets Governance and Incentive Path at Annual Meeting
TipRanks · 2d ago
Regulus Therapeutics names Rekha Garg as chief medical officer
Healthcare Regulus Therapeutics names Rekha Garg as chief medical officer. Garg previously served as the company's senior vice president, clinical development and regulatory. Regulus has over 20 years of experience in the industry. Regulus is a subsidiary of Regulus Pharmaceuticals Inc.
Seeking Alpha · 3d ago
REGULUS THERAPEUTICS ANNOUNCES PROMOTION OF REKHA GARG, M.D., M.S., TO CHIEF MEDICAL OFFICER
Reuters · 3d ago
Press Release: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Dow Jones · 3d ago
Analysts’ Top Healthcare Picks: Xenon (XENE), Progyny (PGNY)
TipRanks · 5d ago
Weekly Report: what happened at RGLS last week (0506-0510)?
Weekly Report · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
TipRanks · 05/10 15:20
Regulus Therapeutics Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/10 14:14
More
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Webull offers Regulus Therapeutics Inc stock information, including NASDAQ: RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.